Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

By C. Louvet, R. Labianca, P. Hammel, G. Lledo, M. Zampino, T. André, A. Zaniboni, Michel Ducreux, E. Aitini, J. Taieb and 3 more. Journal of Clinical Oncology, 2005

988 citations recorded by the source corpus.

Subfields: Biomaterials, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/6e6b162bf03b16f33a6a0fc5e6cddc4278470f37

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

H. Kindler
E. Van Cutsem
D. Schrag
D. Niedzwiecki
W. Scheithauer
J. Kleeff
S. Gillen
M. Moore

Citations in the corpus

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). (2010, background): “Negative phase III results despite promising single-arm phase II data are, unfortunately, a common outcome in pancreatic cancer trials.(3-10) These collective data suggest that in this disease, a single-arm, phase II trial design may not be not optimal.”
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. (2009, result): “Although most studies included patients with metastatic as well as locally advanced disease, several studies have shown different outcomes in these two patient groups.(20,21) The primary objective of the present randomized, placebo-controlled, phase III trial was to show improved OS in patients with”
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages (2010, result): “), but similar to published reports on combination chemotherapy (26.8% response rate”